Introducing the TECENTRIQ Care Guide

A folder featuring informative resources to help support your patients being treated with TECENTRIQ and AVASTIN® (bevacizumab) for 1L unresectable or metastatic hepatocellular carcinoma (HCC).

Inside the folder you'll find the following resources for your patients:

Information on HCC

Understanding Your Disease

An overview of HCC, its symptoms, and treatment options

Where to Find More Information and Support

A list of external organizations your patients can visit for more support

Information on TECENTRIQ

What to Know About TECENTRIQ + Avastin® (bevacizumab)

Results of the TECENTRIQ + Avastin pivotal study in HCC and information on how TECENTRIQ is administered

Options That Can Help You Afford Treatment

Guidance on how Genentech may help your patients get their medicines, regardless of their insurance status

Information on Side Effects and Tips for Management

Learn About Potential Side Effects and Ways to Help Manage Them

A list of common side effects to look out for and tips for managing some of them

My Medication Card

A card to help patients remember their medicines and their healthcare team's contact information

The information offered in the Care Guide is not a replacement for seeking the advice of healthcare providers.

INDICATION

TECENTRIQ, in combination with bevacizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy.

SELECT IMPORTANT SAFETY INFORMATION

Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include immune-mediated serious adverse reactions, including pneumonitis, hepatitis, colitis, endocrinopathies, and other immune-mediated adverse reactions. Other warnings and precautions include infections, infusion-related reactions, and embryo-fetal toxicity.

Please see additional Important Safety Information on the following page and full Prescribing Information.

TECENTRIQ®
atezolizumab 840 mg | 1200 mg INJECTION FOR IV USE

IMPORTANT SAFETY INFORMATION

Serious Adverse Reactions

Please refer to the full Prescribing Information for important dose management information specific to adverse reactions.

- **Immune-mediated pneumonitis.** Immune-mediated pneumonitis or interstitial lung disease, including fatal cases, have occurred. Permanently discontinue TECENTRIQ for Grade 3 or 4 pneumonitis
- **Immune-mediated hepatitis.** Immune-mediated hepatitis and liver test abnormalities, including fatal cases, have occurred. Permanently discontinue TECENTRIQ for AST or ALT elevations more than 8 times the upper limit of normal or total bilirubin more than 3 times the upper limit of normal
- **Immune-mediated colitis.** Immune-mediated diarrhea or colitis have occurred. Permanently discontinue TECENTRIQ for Grade 4 diarrhea or colitis
- **Immune-mediated endocrinopathies.** Thyroid disorders, adrenal insufficiency, type 1 diabetes mellitus, including diabetic ketoacidosis, and hypophysitis/hypopituitarism have occurred
- **Other immune-mediated adverse reactions.** TECENTRIQ can cause severe and fatal immune-mediated adverse reactions. These immune-mediated reactions may involve any organ system. Permanently discontinue TECENTRIQ for Grade 4 immune-mediated adverse reactions involving a major organ
- **Infections.** Severe infections, including fatal cases, have occurred
- **Infusion-related reactions.** Severe or life-threatening infusion-related reactions have occurred. Permanently discontinue TECENTRIQ in patients with Grade 3 or 4 infusion-related reactions
- **Embryo-fetal toxicity.** TECENTRIQ can cause fetal harm in pregnant women. Verify pregnancy status prior to initiating TECENTRIQ. Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose
- Advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose

Most Common Adverse Reactions

The most common adverse reactions (rate ≥20%) in patients who received TECENTRIQ in combination with bevacizumab for HCC were hypertension (30%), fatigue/asthenia (26%), and proteinuria (20%).

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information for additional Important Safety Information.

Genentech
A Member of the Roche Group

©2020 Genentech USA, Inc. All rights reserved. M-US-00004570(v1.0)

TECENTRIQ®
atezolizumab 840 mg / 1200 mg INJECTION FOR IV USE